Provided is an antibacterial biological implant capable of exhibiting superior antibacterial activity stably over a long period of time. Also provided is a method for producing an antibacterial biological implant, the method including subjecting a substrate 2 successively to an anodization treatment, an acid treatment, and an iodine treatment to obtain an antibacterial biological implant 1.

Novel surgical sutures and novel medical devices made from novel semi-crystalline, glycolide-rich A-B-A triblock copolymers of glycolide and lactide, wherein said B-segment is a fully amorphous random copolymer of glycolide and lactide, for long term medical applications are disclosed. The novel polymer compositions are useful for long term absorbable surgical sutures, meshes and other medical devices, especially for patients with compromised healing. The novel sutures have improved properties and improved breaking strength retention, while still substantially absorbing within about a 120-day period post-implantation.

A developable hyaluronic acid microspherical embolic agent includes a hyaluronic acid and an X-ray opaque contrast material; wherein the hyaluronic acid is a modified hyaluronic acid, wherein a modifying method for preparing the modified hyaluronic acid is cross-linking, grafting, esterification, or recombination, and is preferably cross-linking.

A highly safe and inexpensive bone repair material that stably exhibits high antibacterial activity for a long time in a living body by supporting a large amount of an iodine ion and is excellent in apatite forming ability and preservability. The material includes a substrate made of titanium or titanium alloy and a titanate film on a surface of the substrate, the film composed of a large number of crystalline masses having a crystal structure and containing a calcium ion and an iodine ion, wherein the mass contains layers having a TiO skeleton and the calcium and the iodine ions adsorbed between the layers.

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.

A formulation of a discrete liquid patch for the treatment of cold sores or viral lesions, including a combination of the adhesive layer and an active compound/ingredient such as antiviral agents, and/or amino acids, and/or minerals/vitamins. The adhesive layer of the discrete patch is substantially free of hydrocolloid particles. The adhesive layer does not include any backing layer to maintain the compliance of the patch with a thickness ranging from 5 microns to 1,300 microns. Wherein, the discrete patch of the invention is configured to apply to a viral lesion to maintain in contact therewith for a time effective to substantially complete re-epithelialization of the lesion.

The wound dressing described herein can be used as a contact layer dressing. The wound dressing can be positioned between a wound bed and a secondary dressing. The wound dressing can include a layered construction. Each of the layers can include a bioresorbable sponge enclosed within a collagen-based film. The wound dressing can include a plurality of fluid channels that enable fluid flow from the wound bed toward the environment-face side of the wound dressing.

This invention relates to a method for preparing compositions for preventing or treating microbial infections, compositions suitable for use in such treatments and methods for treatment or prevention of infections. One such composition finds particular use in treating mastitis in ruminants. The composition is administered into the udder of an animal as a highly effective treatment for mastitis, or as a prophylactic therapy, by means of an intra-mammary infusion. The milk produced by the animal, during treatment using the composition and method of the invention, is free of residues, such as antibiotics, antimicrobial agents or antimicrobial proteins, which could affect its suitability for drinking or in the production of milk products, such as cheese or yoghurt. The compositions and methods are also useful in treating and preventing lung infections; and infections in burns and wounds; and other infections caused by biofilms. The compositions may also be used on medical devices to prevent infection.

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.

A composition and method for chlorine dioxide production through reaction-diffusion chemistry that facilitates the in situ generation of chlorine dioxide, wherein a dry solid composition of hydroxymethanesulfinic acid monosodium salt dihydrate (abbreviated HMS) and a chlorine dioxide precursor are activated via the addition or absorption of water to produce chlorine dioxide. The dry solid chemical composition comprises dry, safe, transportable reagents that integrate with polymeric materials such as packaging and superabsorbent and stimuli-responsive hydrogel polymers to combine with water to produce chlorine dioxide.